Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Accumulated Expenses (2021 - 2023)

InMed Pharmaceuticals has reported Other Accumulated Expenses over the past 3 years, most recently at $2.3 million for Q1 2023.

  • For Q1 2023, Other Accumulated Expenses changed N/A year-over-year to $2.3 million; the TTM value through Mar 2023 reached $2.3 million, changed N/A, while the annual FY2022 figure was $3.2 million, 43.6% up from the prior year.
  • Other Accumulated Expenses for Q1 2023 was $2.3 million at InMed Pharmaceuticals, down from $2.4 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $3.3 million in Q3 2022 and troughed at $2.2 million in Q2 2021.
  • A 3-year average of $2.7 million and a median of $2.4 million in 2022 define the central range for Other Accumulated Expenses.
  • On a YoY basis, Other Accumulated Expenses climbed as much as 43.6% in 2022 and fell as far as 43.6% in 2022.
  • Year by year, Other Accumulated Expenses stood at $2.2 million in 2021, then grew by 8.37% to $2.4 million in 2022, then decreased by 5.46% to $2.3 million in 2023.
  • Business Quant data shows Other Accumulated Expenses for INM at $2.3 million in Q1 2023, $2.4 million in Q4 2022, and $3.3 million in Q3 2022.